Financial Results, Study Results, and Proposed Merger - Research Reports on Mallinckrodt, Thoratec, WellPoint, Questcor and Regeneron

NEW YORK, August 12, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Thoratec Corp. (NASDAQ: THOR), WellPoint Inc. (NYSE: WLP), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5653-100free.

--
Mallinckrodt PLC Research Reports
On August 7, 2014, Mallinckrodt PLC (Mallinckrodt) reported Q3 FY 2014 financial results (period ended June 27, 2014). Net sales stood at $653.1 million, up 14.6% YoY, driven by the inclusion and performance of OFIRMEV, acquired in March 2014; strong performance in base specialty controlled substance generics portfolio; and positive Methylphenidate ER performance. On a non-GAAP basis, Q3 FY 2014 adjusted net income was $71.6 million, compared with $28.4 million in Q3 FY 2013. The Company also increased its full-year 2014 net sales target to range between $2.35 billion to $2.45 billion, from $2.28 billion to $2.38 billion, forecasted earlier. Further, led by strength of base business and the completed acquisition of Cadence, Mallinckrodt increased 2014 adjusted diluted EPS outlook to range between $4.00 and $4.30 versus $3.30 to $3.60, predicted in May 2014. The full research reports on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/Aug-12-2014/MNK/report.pdf

--
Thoratec Corp. Research Reports
On August 7, 2014, shares of Thoratec Corp. (Thoratec) plunged over 30% to end the trading session at $22.74, a day after the Company reported dismal Q2 FY 2014 (period ended June 28, 2014) financial results. For the quarter, revenues were $118.1 million, as compared to $130.5 million in Q2 FY 2013. GAAP net income was $17.4 million, or $0.30 per diluted share, compared to $23.2 million, or $0.40 per diluted share in Q2 FY 2013. "We are disappointed with the shortfall in our financial results as near-term factors are having a greater than expected negative impact on our business," said Gary F. Burbach, President and CEO. The full research reports on Thoratec are available to download free of charge at:

http://www.analystsreview.com/Aug-12-2014/THOR/report.pdf

--
WellPoint Inc. Research Reports
On August 4, 2014, WellPoint Inc. (WellPoint) reported that as per a study commissioned by its subsidiary, AIM Specialty Health, consumers who chose less expensive MRIs after receiving price information save $220 per test in total health system costs. The study findings which were published in the August edition of Health Affairs also showed that this awareness was linked to a shift in consumer behavior, decreasing the use of high-cost hospital-based MRIs and ultimately reducing price variation between hospital and non-hospital facilities for consumers. "The study showed that consumers are responsive to price information delivered real time as they are making health care decisions," said Sam Nussbaum, WellPoint Chief Medical Officer and Executive Vice President. "And, just as encouraging, is how providers reacted to this shift in consumer utilization-with more than 30 hospitals voluntarily negotiating with our affiliated health plans to lower their MRI pricing to stay competitive in the marketplace." The full research reports on WellPoint are available to download free of charge at:

http://www.analystsreview.com/Aug-12-2014/WLP/report.pdf

--
Questcor Pharmaceuticals, Inc. Research Reports
On August 4, 2014, Questcor Pharmaceuticals, Inc. (Questcor), alongwith Mallinckrodt plc (Mallinckrodt), announced that that two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (ISS) and Glass Lewis, have recommended a vote for the binding proposals relating to Mallinckrodt's acquisition of Questcor pursuant to the Agreement and Plan of Merger dated April 5, 2014. The Company stated that the shareholders are supposed to vote on the transaction at each Company's meeting of shareholders scheduled for August 14, 2014. Further, Questcor's shareholders will also vote on a separate, non-binding proposal related to the merger-related compensation of Questcor's named executive officers. As per the initial terms of the transaction dated April 7, 2014, the acquisition was valued at approximately $5.6 billion and Questcor shareholders will receive $30.00 per share in cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own, for a total approximate consideration of $86.10 per Questcor share. The full research reports on Questcor are available to download free of charge at:

http://www.analystsreview.com/Aug-12-2014/QCOR/report.pdf

--
Regeneron Pharmaceuticals, Inc. Research Reports
On August 5, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) announced Q2 2014 earnings. Revenue increased to $666 million from $458 million during Q2 2013. Non-GAAP net income was up 46.4% YoY to $289.4 million in Q 2 2014, while non-GAAP net income per diluted share was $2.47, as against $1.73 in the prior year period. As per the Company, EYLEA net product sales in the U.S. were $415 million in Q2 2014, compared to $330 million Q2 2013. "Regeneron continued to make progress across all aspects of our business, delivering continued growth and another strong quarter," said Leonard S. Schleifer, M.D., Ph.D., President and CEO of Regeneron." For full year 2014, the Company reaffirmed its guidance for EYLEA net product sales in U.S. to range between $1.7 billion and $1.8 billion. The full research reports on Regeneron are available to download free of charge at:

http://www.analystsreview.com/Aug-12-2014/REGN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review